APA (7th ed.) Citation

Mii, S., Kato, H., Takahara, T., Kojima, M., Kato, Y., Morise, Z., . . . Suda, K. (2025). Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab. World Journal of Surgical Oncology, 23(1), 1. https://doi.org/10.1186/s12957-025-03834-x

Chicago Style (17th ed.) Citation

Mii, Satoshi, Hiroyuki Kato, Takeshi Takahara, Masayuki Kojima, Yutaro Kato, Zenichi Morise, Akihiko Horiguchi, and Koichi Suda. "Prognostic Impact of Neutrophil-to-lymphocyte Ratio (NLR) in Patients with Unresectable Biliary Tract Cancer Treated with Gemcitabine, Cisplatin, and Durvalumab." World Journal of Surgical Oncology 23, no. 1 (2025): 1. https://doi.org/10.1186/s12957-025-03834-x.

MLA (9th ed.) Citation

Mii, Satoshi, et al. "Prognostic Impact of Neutrophil-to-lymphocyte Ratio (NLR) in Patients with Unresectable Biliary Tract Cancer Treated with Gemcitabine, Cisplatin, and Durvalumab." World Journal of Surgical Oncology, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12957-025-03834-x.